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Oral Presentations S221response in six out of eigth patients. In five out of six of these re-
sponding patients we have been able to identify infused T cells using
chimerism analysis and SNP markers specific for the CTL donor.
This method opens up the possibility to rapidly treat patients which
are in acute need of T cell therapy and cannot wait for prolonged ex-
pansion techniques or cannot tolerate standard treatment regiment.
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EXPRESSION OF a4b7 INTEGRIN ON MEMORY CD8+ T-CELLS IS IN-
CREASED IN PATIENTS AT PRESENTATION OF ACUTE INTESTINAL
GRAFT-VS-HOST DISEASE
Chen, Y.-B.1, McDonough, S.2, Chen, H.3, Kennedy, J.1, Ballen, K.K.1,
Dey, B.R.1, McAfee, S.L.1, Spitzer, T.R.1, Jagasia, M.3, Ritz, J.2 1Mas-
sachusetts General Hospital, Boston, MA; 2Dana-Farber Cancer Institute,
Boston, MA; 3Vanderbilt University, Nashville, TN
Background: Acute intestinal graft-vs.-host disease (GVHD) re-
mains a major source of morbidity and mortality after allogeneic he-
matopoietic cell transplantation (HCT). a4b7 integrin is a cell
surface molecule thought to mediate specific lymphocyte trafficking
to intestinal tissue.Our previous work suggested that upregulation of
a4b7 integrin expression on memory CD4+ and CD8+ peripheral
blood T-cells after HCT correlated with the future development
of intestinal GVHD.
Methods: In this analysis, peripheral blood mononuclear cells were
collected from patients at the time of presentation of symptoms of
GVHD prior to the initiation of systemic corticosteroids. In total,
27 patient samples were collected prospectively after HCT, which
were then retrospectively divided into 3 cohorts: GUT (intestinal
GVHD, n 5 11), SKIN (cutaneous GVHD, n 5 9), and NONE
(suggestive symptoms but negative evaluation for GVHD, n 5 7).
Sample collection ranged from day +23 to day +194 after HCT
and was based on symptoms or signs suggestive of GVHD. One pa-
tient developed GVHD after donor leukocyte infusion (DLI).
Results: There were no significant differences in baseline characteris-
tics between the groups. Analysis by flow cytometry showed that GUT
patients had a significantly higher percentage of a4b7 integrin express-
ing memory (defined by CD45RO+) peripheral blood CD8+ T-cells
(median 7.7%, range 0.5%-28.1%) compared to the SKIN group
(2.1%, 0%-3.1%, p 5 0.03), the NONE group (1%, 0.2%-2.2%, p
5 0.02), or the SKIN and NONE groups combined into one NON-
GUT (n5 16) group (1.6%, 0%-3.1%, p5 0.01). Time of sample col-
lection after HCT had no effect on the expression of a4b7 integrin.
Conclusion: These results add to the evidence that upregulation of
a4b7 integrin on memory CD8+ T-cells may be involved in lympho-
cyte trafficking in acute intestinal GVHD and increased expression
may be a potential biomarker. More importantly, a4b7 integrin may
represent a novel target of treatment and prophylaxis of acute intestinal
GVHD after HCTwith specific monoclonal antibodies already in de-
velopment for the treatment of inflammatory bowel disease. Analysis
with a larger number of samples is planned to confirm these results.
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INFUSION OF SYNGENEIC APOPTOTIC CELLS PRIOR TO BONE MARROW
TRANSPLANTATION DECREASES TCELL PROLIFERATION AND IN-
CREASES SURVIVAL
Florek, M., Sega, E.I., Mueller, A.M.S., Leveson-Gower, D.B.,
Shizuru, J.A., Negrin, R.S. Stanford University, Stanford, CA
To prevent graft versus host disease (GVHD) the graft has to be
rendered tolerant to avoid alloreactivity towards the host. One
promising approach to induce tolerance is to administer apoptotic
cells to the host. Apoptosis can be induced by extracorporeal photo-
pheresis (ECP), a therapy based on exposure of cells to photoactiv-
able 8-methoxypsoralen (8MPO) and UVA irradiation. The effect
of ECP treatment is at least in part, due to alteration of dendritic
cell (DC) maturation, leading to reduced Tcell activation. In con-
trast to clinical practice where ECP is only applied to established
GVHD, we have developed a pre-emptive murine model with the
aim of inhibiting the initiation phase of acute GVHD.
Methods: Host apoptotic splenocytes were infused into MHC
matched or mismatched recipients 5 or 2 days prior to lethal irradi-ation and BMT. Apoptotis of cells was generated by 8-MPO and
UVA light (UVAR light set, Therakos). Mice were followed for
GVHD score and survival.
Results: ECP-treated mice survived longer both across major (me-
dian survival 51 versus 26 days, p\0.0001) and minor (median sur-
vival 56.5 versus 9 days, p\0.002) MHC barriers. Importantly,
even though ECP treatment promoted tolerance against the host it
did not impact the graft versus tumor effect in a B-cell lymphoma
model. In vivo experiments using bioluminescent imaging showed
reduced CD4+Tcell proliferation during the initiation phase of
GVHD (day+4) in ECP-treated mice compared to mice receiving
Tcon only. The same result was found in CFSE labeled Tcells re-
isolated on day+4. FACS-sorted DC incubated with apoptotic cells
for 2 days in vitro showed a diminished capability to induce Tcell
proliferation. Re-isolation experiments on day+3 confirmed lower
expression of homing (P-Selectin, a4b7) and activation (CD44,
CD69) markers on donor Tcells in ECP treated groups, indicating
slower trafficking to GvHD target organs. Furthermore, at day+7
ECP-treated groups showed increased FoxP3-expressing host Tregs
in comparison to control groups whereas donor Treg were similar in
both groups.
In summary, ECP treatment prior to transplantation led to a sig-
nificant survival benefit with no impact on graft versus tumor effect;
reduced CD4+ Tcell proliferation; delayed expression of homing
and activation markers during the initiation phase of GVHD and
an increase in host Treg. Overall our work suggests that pre-emptive
ECP of host cells prior to BMT may be a clinically relevant strategy
to prevent acute GVHD.51
LOW LEVELS OF 25-HYDROXYVITAMIN D PRIOR TO ALLOGENEIC
TRANSPLANTATION CORRELATEWITH THE DEVELOPMENT OF CHRONIC
GRAFT-VERSUS-HOST DISEASE
Glotzbecker, B.E.1, Ho, V.T.1, Aldridge, J.1, Kim, H.T.1, Horowitz, G.2,
Ritz, J.1, Soiffer, R.J.1, Avigan, D.2, Rosenblatt, J.2 1Dana Farber Cancer
Institute, Boston,MA; 2Beth Israel Deaconess Medical Center, Boston,MA
Graft-versus-host disease (GVHD) remains a significant cause
of morbidity and mortality following allogeneic hematopoietic
stem cell transplantation. GVHD is mediated by the activation
and expansion of donor derived alloreactive lymphocytes stimu-
lated in part by residual host dendritic cells (DCs) and donor
DCs with cross presentation of alloantigens. Vitamin D is a hor-
mone essential for calcium homeostasis and exhibits potent immu-
nomodulatory characteristics. We have demonstrated that vitamin
D exposure inhibits DC maturation and DC mediated stimulation
of allogeneic T cells. As such, we hypothesized that vitamin D de-
ficiency may result in the enhanced capacity of DCs to induce
GVHD. In this study, we performed a retrospective case-control
study to evaluate whether monohydroxyvitamin D levels measured
in serum samples obtained from patients prior to allogeneic trans-
plantation were predictive of the risk for GVHD. Fifty-three pa-
tients aged 18-60 who underwent a myeloablative matched related
or matched unrelated donor transplant between December 2000
and December 2009 were included in the analysis. 25-OH vitamin
D concentrations were measured by an ELISA assay prior to
transplantation. The median 25-OH vitamin D level was 21.9
ng/mL (range 7.8-45.7). Patients were divided into two cohorts
based on a vitamin D level: \ 25 ng/mL (32 patients) or $25
ng/mL (21 patients). Remarkably, the cumulative incidence (CI)
of chronic GVHD (cGVHD) at 2 years in patients with 25-OH
vitamin D \25 was 63.8%, compared to 23.8% in patients with
vitamin D levels $ 25 (p 5 0.009). Similarly the 2 year CI of ex-
tensive cGVHD was significantly greater in patients with vitamin
D levels\25 compared to those with $25 (54.5% versus 14.3%,
p 5 0.005). This result is consistent in multivariable competing
risks model for which patient and transplant related factors men-
tioned above were adjusted (HR 5.26, p 5 0.02). Three-year pro-
gression-free survival and overall survival were similar between the
two groups (51% vs. 47%, p 5 0.61; and 53% vs. 50%, p 5 0.57
respectively). In summary, vitamin D deficiency prior to allogeneic
transplantation is associated with a significantly increased risk of
chronic GVHD. A prospective clinical trial evaluating the use of
vitamin D for the prevention of chronic GVHD is planned.
